JPM 2023 Coherus.pdf

1、Copyright 2023.All rights reserved.January 10,202341stAnnual J.P.Morgan Healthcare Conference Presentation2Except for the historical information discussed today and contained herein,the matters discussed today and set forth in this presentation are forward-looking statements within the meaning of th

2、e“safe harbor”provisions of the Private Securities Litigation Reform Act of 1995,including,but not limited to,statements regarding consistent future revenue growth,projected revenues in 2026,our ability to advance our pre-clinical product candidates;our ability to launch products and product candida

3、tes as planned in 2023 and afterwards;our ability to successfully close on the transaction to acquire commercial rights to a biosimilar candidate to Eylea in Q1 2023 or at all;our projections for the size and growth of the anti-VEGF market and other markets and our ability to gain market share or re

4、venue growth in any of the markets for our other products and product candidates;our projections about commercial synergies that may exist between our products and product candidates;our future ability to scale our ophthalmology franchise;our projections for sales of CIMERLI in the future;our abilit

5、y to expand payer coverage;our projections for market size for UDENYCA OBI;our ability to gain approval for our product candidates in the future with the FDA;our ability to establish our products and product candidates as the standard of care for first-line treatment;expectations about the size of t

6、he market for YUSIMRY and our ability to compete to gain share in a large market;and our expectations about our capacity to supply the adalimumab market.Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus actual results,performance or achievements to